According to the Zhitong Finance App, Kang Feng Bio-B (06922) announced its 2023 results, with revenue of about 40.95 million yuan, up 50.8% year on year; gross profit of 31.05 million yuan, up 60.4% year on year; parent company owners should account for loss of 97.486 million yuan, a year-on-year decrease of 13.13%; loss per share.

According to the announcement, revenue growth was mainly driven by increased sales of bladder cryoablation systems, pulmonary nodule locators, and endoscopic anastomosis clips.